With no offer forthcoming, EKF plans to appoint 8% shareholder and industry veteran Ron Zwanziger as Chairman with a mandate to accelerate growth, presumably through further M&A. It is unclear whether the plan is still to demerge the Molecular Diagnostics division. The immediate focus however needs to be on stabilising the business and landing some of the tender orders that remain outstanding, thus helping restore some confidence in forecasts and the outlook.
26 Oct 2015
Offer talks terminated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Offer talks terminated
EKF Diagnostics Holdings plc (EKF:LON) | 28.1 0 0.4% | Mkt Cap: 127.5m
- Published:
26 Oct 2015 -
Author:
Chris Glasper -
Pages:
3
With no offer forthcoming, EKF plans to appoint 8% shareholder and industry veteran Ron Zwanziger as Chairman with a mandate to accelerate growth, presumably through further M&A. It is unclear whether the plan is still to demerge the Molecular Diagnostics division. The immediate focus however needs to be on stabilising the business and landing some of the tender orders that remain outstanding, thus helping restore some confidence in forecasts and the outlook.